Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + azacitidine + donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Cell Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Venetoclax + azacitidine + donor lymphocyte infusion is a combination therapy used primarily for the treatment of relapsed or refractory acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Venetoclax is a small molecule inhibitor of B-cell lymphoma 2 (BCL2), promoting apoptosis in cancer cells. Azacitidine is a hypomethylating agent that inhibits DNA methyltransferase, leading to DNA hypomethylation and cytotoxicity in abnormal hematopoietic cells. Donor lymphocyte infusion (DLI) involves the administration of white blood cells from the original stem cell donor to enhance graft-versus-leukemia effects by boosting immune-mediated destruction of residual leukemia cells. This combination has shown efficacy and tolerability in patients with relapsed AML after allo-HSCT, with reported objective remission rates above 60% and manageable adverse events[1][2][3].
- Other names
- VENAZADLI
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on venetoclax + azacitidine + donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + azacitidine + donor lymphocyte infusion.